Menu

Senate Passes GMO Labeling Bill

The legislation will now go to the US House of Representatives, where it will likely pass.

Jul 12, 2016
Bob Grant

WIKIMEDIA, USDAConsumers may soon have access to information indicating if their food products include ingredients that are genetically modified. Last week (July 7) the US Senate voted 63 to 30 in favor of passing a bill to federally mandate the labeling of foods that contain genetically modified organisms (GMOs).

Critics of the bill don’t like key parts of the legislation. There are no penalties for manufacturers who fail to comply with the mandate. And the bill only requires food companies to include a US Department of Agriculture (USDA) symbol indicating the presence of a GMO in the product or a QR code that links smartphone users to ingredient information, rather than explicitly listing the GMO ingredients. According to Science, Senator Patrick Leahy (D-VT)—whose state passed a GMO labeling bill that went into effect on July 1—called the bill “a farce of a proposal.”

“It certainly is not perfect, from my perspective,” said Pat Roberts (R-KS), one of the architects of the bill, “but it is the best bill possible under these difficult circumstances we find ourselves in today.”

According to the Food & Environment Reporting Network (FERN), the US House of Representatives may vote on the bill as early as Wednesday (July 13), and it is likely to pass there as well. Pundits are unsure whether President Barack Obama will sign the bill into law, FERN reported.

Update (July 14): The US House of Representatives has passed the GMO labeling bill by a 306 to 117 margin today. According to The Hill, President Obama is expected to sign the bill into law despite objections from Congressional Democrats and consumer groups.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!